Why hematocrit rises on TRT
Testosterone increases erythropoietin (EPO) production from the kidneys, which signals bone marrow to produce more red blood cells. Hematocrit (the percentage of blood volume that is red cells) rises accordingly. This is a normal physiologic response, not a complication per se.
Subcutaneous TRT and lower-frequency injections produce smaller hematocrit elevations than high-dose biweekly intramuscular injections. Weekly or twice-weekly subcutaneous protocols typically produce mild rises that stabilize.
The actual thresholds
| Hematocrit (%) | Action |
|---|---|
| <48 | No action; monitor at next regular interval |
| 48-52 | Continue monitoring; ensure hydration; rule out sleep apnea |
| 52-54 | Address contributors; consider dose adjustment; donate blood |
| >54 | Therapeutic phlebotomy and/or dose reduction |
| >58 | Hold TRT until normalized |
The real risk
The fear: thick blood causes clots. The reality: clinically meaningful clotting risk emerges at hematocrit >55% with other risk factors. Recent analyses of large TRT cohorts have found minimal cardiovascular event increase even at hematocrit 50-54% in otherwise healthy men. The TRAVERSE trial, which monitored hematocrit closely, did not show increased clotting events on TRT.
That said: men with prior DVT, atrial fibrillation, smoker status, or polycythemia vera have legitimate reasons to keep hematocrit lower. Individual context matters.
Contributing factors
- Sleep apnea, undiagnosed OSA is the most common driver of severe TRT-related polycythemia. Test for it.
- Dehydration, chronic low fluid intake artificially inflates hematocrit
- Higher doses, >200 mg/week of testosterone cypionate raises hematocrit faster
- IM vs SC, IM produces higher peaks, more EPO stimulation
- Less frequent injections, once-every-two-weeks creates supraphysiologic peaks
- Smoking, COPD, independently raise hematocrit
- Altitude, living at high altitude raises baseline
Management protocol
- Monitor at month 3, 6, 12, then annually.
- Hydrate aggressively, >2.5L/day water
- Rule out sleep apnea if OSA risk factors present
- Switch to subcutaneous if currently on IM
- Increase frequency, twice weekly produces lower peaks than once weekly
- Donate blood every 8-12 weeks if possible, most efficient hematocrit drop
- Therapeutic phlebotomy if blood donation isn't feasible, typically every 8-12 weeks
- Reduce TRT dose if combined with other measures isn't enough
- Discontinue TRT only as last resort
The clinical pearl: Most "TRT polycythemia" is sleep apnea polycythemia revealed by TRT. Address the OSA and the hematocrit normalizes.
Bottom line
Hematocrit elevation on TRT is common but rarely the reason to discontinue therapy. With proper monitoring, simple lifestyle adjustments, and occasional blood donation, most men maintain a stable hematocrit in the 47-51% range, well within the safe window. The fear of polycythemia is mostly overblown; the actual management is straightforward.